MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25 th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.
Since the Company’s inception, MaxCyte set out to commercialize Flow Electroporation ® technology with a talented global team and, over the years, we have developed and launched a suite of products within our proprietary ExPERT TM platform,” Maher Masoud, President and CEO, MaxCyte “Today, we are proud to provide our customers with best-in-class electroporation solutions and tools. Knowing that our customers and their patients come first drives us to find the solutions to meet their needs as we enter the next era of scientific discovery and development focused on cell and gene therapy .” MaxCyte’s Flow Electroporation technology was used to support the development of CASGEVY ® , the industry’s first, FDA-approved, non-viral cell therapy.
Under Strategic Platform License (SPL) agreements, the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics on this first-of-its-kind CRISPR/Cas9 genome-edited cell therapy. In total, MaxCyte h.
